Assessment of Real-World Treatment Patterns and Outcomes In Relapsed or Refractory Multiple Myeloma: Evidence From A Brief Multi-Country Survey of European Physicians.
نویسندگان
چکیده
Assessment of Real-World Treatment Patterns and Outcomes in Relapsed or Refractory Multiple Myeloma: Evidence From a Brief Multicountry Survey of European Physicians Keith L Davis, Huamao Mark Lin, Ai-Min Hui, Shumin Zhang, James A Kaye RTI Health Solutions, Research Triangle Park, NC, United States; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, United States; Takeda Development Center Americas, Deerfield, IL, United States; RTI Health Solutions, Waltham, MA, United States
منابع مشابه
Characteristics and outcomes of patients with multiple myeloma : Data from a developing country
Background: Multiple myeloma (MM) is a plasma cell disorder characterized by presence of monoclonal protein in serum or urine or both, increased bone marrow plasma cells, osteolytic lesion, hypercalcemia, and anemia. Several combination regimens are commonly recommended for treatment of multiple myeloma. The present study aimed at determining the characteristics and outcomes of patients with mu...
متن کاملUpfront Overall Survival Modelling in Comparison to Real World Data: Lenalidomide for the Treatment of Multiple Myeloma Patients in South Korea.
Decision makers are frequently faced with the question of how realistic are cost-effectiveness models. Overall survival (OS) is a desired clinical trial and health technology assessment endpoint but frequently unrealistic or elusive at the point of new drugs financing decision. We aim to compare the overall survival from lenalidomide treatment in relapsed/refractory multiple myeloma (rrMM) pati...
متن کاملDouble Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM therapy. Median OS in this cohort was 5.6 months...
متن کاملThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway. In August 2015, the European Commission authorized panobinostat for use in combination with bortezomib and dexamethasone for the treatment of relapsed or relapsed and refractory multiple myeloma (MM) in patients who have received...
متن کاملCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors.
While survival times have increased over the last decade, most patients with multiple myeloma (MM) eventually relapse and become refractory to therapy. The treatment of patients with relapsed and/or refractory MM is frequently further complicated by the presence of pre-existing comorbidities that arise from an advanced disease state and of toxicities stemming from prior antimyeloma treatment. C...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 18 7 شماره
صفحات -
تاریخ انتشار 2015